44
Participants
Start Date
February 29, 2016
Primary Completion Date
April 30, 2025
Study Completion Date
February 28, 2027
MultiTAA-specific T cells
"The 5 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2; Dose Level Four: 5 x 10e7 cells/m2; Dose Level Five: 1 x 10e8 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.~In patients being treated as adjuvant therapy or if patients with residual disease, have a complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions (or below the patient's original dose can be administered) at least 4 weeks apart."
Houston Methodist Hospital, Houston
Texas Children's Hospital, Houston
The Methodist Hospital Research Institute
OTHER
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
American Society for Blood and Marrow Transplantation (ASBMT)
UNKNOWN
Cancer Prevention Research Institute of Texas
OTHER
Baylor College of Medicine
OTHER